MARKETABLE SECURITIES (Details Narrative) - USD ($) |
3 Months Ended | 12 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2017 |
Sep. 30, 2022 |
|
| Restructuring Cost and Reserve [Line Items] | ||||
| Marketable securities, unrealized gain (loss) | $ (2,000) | $ 5,400 | ||
| Marketable securities | $ 1,700 | $ 3,700 | ||
| Amarantus BioScience Holdings, Inc. [Member] | ||||
| Restructuring Cost and Reserve [Line Items] | ||||
| Stock issued during period, shares, acquisitions | 1,000,000 | |||
| Stock issued during period, value, acquisitions | $ 40,980 | |||
| X | ||||||||||
- Definition Amount of investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of unrealized gain (loss) on investment in marketable security. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of shares of stock issued during the period pursuant to acquisitions. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Value of stock issued pursuant to acquisitions during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|